GLP-1 Drugs and Muscle Loss: What You Need to Know

If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication and you've noticed your grip feels weaker or your workouts feel harder, you're not imagining things. Researchers are now asking the same question you might be: does losing weight this fast come at the cost of your muscle?

The short answer is that some muscle loss during GLP-1 therapy is real, but the full picture is more nuanced than the headlines suggest.

Why Researchers Are Paying Attention to This Now

Weight loss drugs based on GLP-1 receptor agonists (a class of medications that mimic a natural gut hormone to reduce appetite and slow digestion) have produced remarkable results in clinical trials. Patients on semaglutide, the active ingredient in Ozempic and Wegovy, lost an average of 15% of body weight in major trials. Those on tirzepatide, the dual-action ingredient in Mounjaro, lost even more.

But rapid weight loss from any cause, whether it's dieting, surgery, or medication, doesn't come purely from fat. The body also breaks down some lean tissue, including muscle, during a large calorie deficit.

This has prompted researchers at institutions across the country to look more carefully at what's actually happening to patients' bodies. A new study based in St. Louis is specifically recruiting participants to track changes in muscle strength and physical performance during GLP-1 treatment. It's one of several ongoing investigations trying to move beyond scale weight and understand what these drugs are doing at the tissue level.

What "Muscle Loss" Actually Means on These Medications

Before you panic, it helps to understand what researchers mean when they say muscle loss.

Lean Mass vs. Functional Strength

Losing some lean mass during a calorie deficit is nearly universal. When you eat significantly less, your body draws on stored energy, and some of that comes from protein stores in muscle. The more important clinical questions are how much muscle is lost, whether strength and function are affected, and whether the loss is proportional compared to other weight loss methods.

Early data from semaglutide trials suggested that roughly 25 to 40% of the total weight lost could be lean mass. That sounds alarming, but it's worth noting that the same ratio is typical for other calorie-restriction approaches. Obesity itself is also associated with poor muscle quality, so some of what gets measured as "lean mass" in people with obesity may not be high-quality functional tissue to begin with.

The more pressing concern is whether GLP-1 users are experiencing measurable declines in grip strength, walking speed, or the ability to perform everyday tasks. That's what the St. Louis study and others like it are designed to find out.

Why Older Adults Face Higher Risk

For most younger, active adults, losing some lean mass during a weight loss period is manageable and often reversible. For older adults, especially those over 60, it's a different story.

Age-related muscle loss, called sarcopenia, is already a serious health concern. If GLP-1 therapy accelerates that process without countermeasures, it could leave older patients weaker and at higher risk for falls, fractures, and loss of independence. This is one reason why doctors and researchers are paying particular attention to this age group.

What the Current Evidence Actually Shows

The science here is still developing, and it's important to separate what we know from what's still being investigated.

Clinical Trial Data

In the STEP trials for semaglutide (the major studies behind Wegovy's approval), participants lost significant amounts of weight but were not routinely assessed for muscle strength or functional performance. Body composition was measured in some sub-studies using DEXA scans (a type of imaging that measures fat, bone, and lean tissue separately), and results suggested fat mass decreased more than lean mass in relative terms.

A 2023 analysis published in the journal Obesity found that patients on semaglutide lost proportionally more fat than lean tissue compared to placebo groups following a diet-only approach. That's a meaningful finding, but it doesn't tell us everything about functional strength.

Tirzepatide data from the SURMOUNT trials showed similar patterns, with substantial fat loss and relatively preserved lean mass in percentage terms. But again, functional strength outcomes weren't the primary focus of those trials.

What's Still Unknown

What the existing trials don't answer well is whether the absolute amount of muscle lost is clinically significant, how strength changes over multi-year treatment periods, and whether stopping the drug causes a different pattern of weight regain that disproportionately replaces muscle with fat.

That last point is particularly important. Some researchers have raised concerns that if patients stop GLP-1 therapy and regain weight, the regained weight may be predominantly fat rather than muscle, leaving them worse off than before in terms of body composition.

These are exactly the kinds of questions the St. Louis study and similar trials are designed to address.

How to Protect Your Muscle While on GLP-1 Therapy

You don't need to wait for researchers to finish their studies to take action. There are well-established, evidence-backed strategies for preserving muscle during any weight loss program, and they apply directly to GLP-1 therapy.

Prioritize Resistance Training

Lifting weights or doing resistance-based exercise is the single most effective tool for preserving lean mass during a calorie deficit. You don't need to become a competitive powerlifter. Two to three sessions per week of bodyweight exercises, resistance bands, or free weights is enough to send a meaningful signal to your muscles to maintain themselves.

If you're new to exercise or have physical limitations, a physical therapist or certified trainer can help you build a safe routine that matches your current fitness level.

Eat Enough Protein

Protein is the raw material your body uses to maintain and repair muscle tissue. During GLP-1 therapy, many patients experience significantly reduced appetite, which makes it easy to under-eat protein without realizing it.

Most evidence-based guidelines for people actively trying to preserve muscle during weight loss recommend 1.2 to 1.6 grams of protein per kilogram of body weight per day. For a 200-pound person, that's roughly 109 to 145 grams of protein daily. Prioritizing high-protein foods at each meal, and possibly using a protein supplement if your appetite is very low, can help you hit that target.

Don't Drop Calories Too Aggressively

GLP-1 medications are powerful appetite suppressants. Some patients find their intake drops dramatically in the first weeks of treatment. While this drives fast early weight loss, eating too few calories can accelerate muscle breakdown.

Work with your prescribing provider or a registered dietitian to establish a reasonable calorie floor, a minimum daily intake that supports weight loss without compromising muscle maintenance.

Questions to Ask Your Doctor Before and During Treatment

Your prescribing provider may not routinely bring up muscle health unless you ask. Here are specific questions worth raising at your next appointment.

Before Starting

• Should we get a baseline DEXA scan to measure my current body composition so we have a reference point for tracking whether weight loss is coming from fat or lean tissue?
• Are there any reasons my age, activity level, or health history put me at higher risk for muscle loss during GLP-1 therapy, and should we take additional precautions?
• What protein intake and exercise routine would you recommend alongside my GLP-1 medication to protect lean mass from the start of treatment?

During Treatment

• How are we tracking my muscle mass, not just my weight, and should we schedule periodic DEXA scans, bioelectrical impedance tests, or functional strength assessments?
• If I am losing lean mass at a concerning rate, should we adjust my dose, slow the titration, or change our approach before the loss becomes functionally significant?
• Are there newer formulations or companion therapies being studied to specifically protect muscle during GLP-1 treatment, and would any clinical trials be appropriate for me?

These questions signal to your provider that you're thinking about long-term health, not just short-term weight loss, and they open the door for a more complete monitoring plan.

Emerging Research and Next-Generation Approaches

The muscle loss question has sparked real momentum in pharmaceutical research. Several companies are now developing drugs that pair GLP-1 receptor activity with mechanisms specifically designed to protect or build muscle.

One approach under investigation involves combining GLP-1 receptor agonism with activin receptor blockers, which are compounds that help prevent muscle breakdown. Early trials are showing promise, though these combinations are years away from reaching patients outside of clinical studies.

Separately, some clinicians are already experimenting with structured resistance training programs as a formal component of GLP-1 treatment, rather than an afterthought. A few telehealth providers offering GLP-1 prescriptions are beginning to include coaching or dietitian access as part of their service models. You can compare current Best Providers to see which ones include this kind of support.

The field is moving quickly, and the St. Louis study is one of many that will help clarify exactly how much muscle risk exists and what the best countermeasures are.

The Cost Angle: Why This Research Matters Beyond the Lab

There's a practical financial dimension to this conversation that doesn't get discussed enough. If muscle loss from GLP-1 therapy leads to functional decline, falls, fractures, or increased need for physical therapy, those costs add up quickly.

For patients already managing the high out-of-pocket cost of GLP-1 medications (often $900 to $1,400 per month without insurance), the idea of additional healthcare costs from preventable side effects is concerning.

This is one more reason to be proactive about muscle health from the start of treatment rather than addressing it after problems develop. If cost is a barrier to staying on your medication consistently, check out available GLP-1 Coupons that may reduce your monthly expense.